Libevitug Biosimilar - Research Grade

Human

HBV

>1mg/ml

IgG1 - lambda2

CHO Cells

Exbivirumab Biosimilar - Research Grade (ICH5540), Lenvervimab Biosimilar - Research Grade (ICH5632), Libivirumab Biosimilar - Research Grade (ICH5642), Tobevibart Biosimilar - Research Grade (ICH5931), Tuvirumab Biosimilar - Research Grade (ICH5950)

https://www.imgt.org/mAb-DB/

ICH3002

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of libevitug, supplied for research use only. Libevitug is a fully human anti-PreS1 IgG1 monoclonal antibody (originator designation HH-003) that neutralizes hepatitis B and D virus infection by binding the PreS1 domain of the HBV large surface (envelope) protein and blocking its engagement of the hepatocyte entry receptor NTCP. The research-grade analog is built around this same viral-antigen specificity, allowing investigators to study PreS1 recognition, virus-neutralization, and entry-blockade in controlled experiments without using clinical material. It is useful as a positive binding and neutralization control, a reference reagent for comparability and assay development, a benchmark in HBV/HDV entry-inhibitor screening, and a tool for antibody-engineering and ADCC/effector-function studies. It is offered at research grade with low endotoxin (typically <1 EU/mg, with an ultra-low <0.5 EU/mg option), and can be provided in bulk milligram-to-gram quantities for in-vitro and preclinical workflows. It is not the clinical drug and is not intended for human or veterinary use. The target is the PreS1 region of the hepatitis B virus (HBV) large (L) surface envelope protein. HBV is an enveloped, partially double-stranded DNA hepadnavirus that establishes chronic hepatic infection and is the obligate helper virus for hepatitis D virus (HDV), which packages its genome inside HBV envelope proteins. The N-terminal PreS1 domain of the L protein mediates the initial, high-affinity attachment step of viral entry by binding sodium taurocholate co-transporting polypeptide (NTCP/SLC10A1), the bile-acid transporter that serves as the functional entry receptor on hepatocytes. Because both HBV and HDV share this envelope and entry route, PreS1 is a validated antigen for entry-blocking neutralization. Chronic HBV, and especially HBV/HDV co-infection, drives cirrhosis and hepatocellular carcinoma, making the PreS1-NTCP interaction a central antiviral target.

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Libevitug biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Libevitug biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Libevitug biosimilar target?

A: It is a non-therapeutic biosimilar of Libevitug used as a binding and neutralization reagent against HBV; for research use only.